Tag Archives: Carcinoid syndrome

March, 2017

  • 1 March

    FDA Approves Lexicon’s Xermelo for Carcinoid Syndrome Diarrhea

    The Woodlands, Texas, February 28, 2017 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the U.S. Food and Drug Administration (FDA) has approved XERMELO™ (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) …

September, 2016

  • 15 September

    FDA Extends PDUFA Date for Lexicon’s Carcinoid Syndrome Drug

    THE WOODLANDS, Texas, Sept. 14, 2016 /PRNewswire/ — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (“FDA”) will require additional time to complete its review of the New Drug Application (“NDA”) for telotristat etiprate, an oral drug for the treatment of carcinoid syndrome.  In …